Compare VENUS REMEDIES with J.B.Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs J.B.CHEMICALS - Comparison Results

J.B.CHEMICALS 
   Change

JB Chemicals and Pharmaceuticals Limited (JBCPL), the flagship of the Unique Group, is one of the India's leading transnational pharmaceutical company. The company has 11 manufacturing facilities at four locations in India (Belapur, Ankleshwar, Panol... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES J.B.CHEMICALS VENUS REMEDIES/
J.B.CHEMICALS
 
P/E (TTM) x -13.7 38.5 - View Chart
P/BV x 0.9 7.2 12.8% View Chart
Dividend Yield % 0.0 0.2 -  

Financials

 VENUS REMEDIES   J.B.CHEMICALS
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
J.B.CHEMICALS
Mar-18
VENUS REMEDIES/
J.B.CHEMICALS
5-Yr Chart
Click to enlarge
High Rs126363 34.7%   
Low Rs61255 24.0%   
Sales per share (Unadj.) Rs301.8169.1 178.4%  
Earnings per share (Unadj.) Rs-24.916.6 -149.8%  
Cash flow per share (Unadj.) Rs2.523.4 10.9%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.6 0.0%  
Book value per share (Unadj.) Rs293.3172.5 170.0%  
Shares outstanding (eoy) m12.3483.57 14.8%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x0.31.8 17.0%   
Avg P/E ratio x-3.818.6 -20.2%  
P/CF ratio (eoy) x36.713.2 278.4%  
Price / Book Value ratio x0.31.8 17.8%  
Dividend payout %012.0 0.0%   
Avg Mkt Cap Rs m1,15425,827 4.5%   
No. of employees `0000.93.8 24.5%   
Total wages/salary Rs m3932,511 15.7%   
Avg. sales/employee Rs Th4,026.13,747.4 107.4%   
Avg. wages/employee Rs Th425.0665.7 63.8%   
Avg. net profit/employee Rs Th-331.8367.8 -90.2%   
INCOME DATA
Net Sales Rs m3,72414,135 26.3%  
Other income Rs m23366 6.2%   
Total revenues Rs m3,74714,501 25.8%   
Gross profit Rs m3952,178 18.1%  
Depreciation Rs m338570 59.4%   
Interest Rs m35435 1,015.2%   
Profit before tax Rs m-2751,940 -14.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m32552 5.7%   
Profit after tax Rs m-3071,387 -22.1%  
Gross profit margin %10.615.4 68.8%  
Effective tax rate %-11.528.5 -40.3%   
Net profit margin %-8.29.8 -84.0%  
BALANCE SHEET DATA
Current assets Rs m2,63810,470 25.2%   
Current liabilities Rs m2,3052,749 83.8%   
Net working cap to sales %8.954.6 16.4%  
Current ratio x1.13.8 30.1%  
Inventory Days Days13555 245.4%  
Debtors Days Days4678 59.7%  
Net fixed assets Rs m4,8715,811 83.8%   
Share capital Rs m123167 73.8%   
"Free" reserves Rs m3,49614,248 24.5%   
Net worth Rs m3,61914,416 25.1%   
Long term debt Rs m1,3740-   
Total assets Rs m7,50917,649 42.5%  
Interest coverage x0.256.6 0.4%   
Debt to equity ratio x0.40-  
Sales to assets ratio x0.50.8 61.9%   
Return on assets %0.68.1 7.8%  
Return on equity %-8.59.6 -88.1%  
Return on capital %1.613.7 11.6%  
Exports to sales %00-   
Imports to sales %13.90-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m517NA-   
Fx inflow Rs m06,164 0.0%   
Fx outflow Rs m5171,334 38.7%   
Net fx Rs m-5174,829 -10.7%   
CASH FLOW
From Operations Rs m5141,231 41.8%  
From Investments Rs m-123-208 59.2%  
From Financial Activity Rs m-387-595 65.0%  
Net Cashflow Rs m4427 1.0%  

Share Holding

Indian Promoters % 32.9 55.4 59.3%  
Foreign collaborators % 0.0 0.3 -  
Indian inst/Mut Fund % 0.2 3.4 5.3%  
FIIs % 0.6 3.9 14.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 37.0 179.5%  
Shareholders   20,121 30,437 66.1%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   IPCA LABS  SANOFI INDIA  ALEMBIC PHARMA  PROCTER & GAMBLE HEALTH  SHASUN PHARMA  

Compare VENUS REMEDIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Flat; Wipro & Hindalco Industries Among Top Nifty Gainers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

J.B.CHEMICALS Announces Quarterly Results (3QFY20); Net Profit Up 34.1% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, J.B.CHEMICALS has posted a net profit of Rs 622 m (up 34.1% YoY). Sales on the other hand came in at Rs 4 bn (up 9.3% YoY). Read on for a complete analysis of J.B.CHEMICALS's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

J.B.CHEMICALS Announces Quarterly Results (4QFY19); Net Profit Up 91.2% (Quarterly Result Update)

May 24, 2019 | Updated on May 24, 2019

For the quarter ended March 2019, J.B.CHEMICALS has posted a net profit of Rs 422 m (up 91.2% YoY). Sales on the other hand came in at Rs 4 bn (up 18.9% YoY). Read on for a complete analysis of J.B.CHEMICALS's quarterly results.

J.B.CHEMICALS Announces Quarterly Results (3QFY20); Net Profit Up 34.1% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, J.B.CHEMICALS has posted a net profit of Rs 622 m (up 34.1% YoY). Sales on the other hand came in at Rs 4 bn (up 9.3% YoY). Read on for a complete analysis of J.B.CHEMICALS's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Unique Sector for Short-Term Profits(Fast Profits Daily)

Apr 12, 2021

This ignored sector could deliver big short-term profits.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Apr 16, 2021 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 8-QTR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS